Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia clinical trials

Explore recruiting relapsed or refractory b cell acute lymphoblastic leukemia clinical trials.

Recruiting relapsed or refractory b cell acute lymphoblastic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia

Germany, Italy, Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)

France, Italy, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia trials by city

Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Toronto Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Vancouver Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Montreal Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Calgary Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Edmonton Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Ottawa Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Winnipeg Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Quebec City Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Hamilton Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Kitchener Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in London Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Halifax Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in New York Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Los Angeles Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Chicago Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease